TELO

Telomir-1's Effectiveness: Telomir Pharmaceuticals announced that its compound Telomir-1 significantly reduces tumor size by about 50% in a prostate cancer model and protects against chemotherapy-induced toxicity when used with Paclitaxel.

Future Research and Applications: The company is also exploring Telomir-1 for age-related diseases and plans to submit an Investigational New Drug application by the end of the year, highlighting its potential in regulating copper metabolism for conditions like Wilson's disease.

Surge in Biotech Interest: Several biotech companies, including Silexion Therapeutics and 60 Degrees Pharmaceuticals, are experiencing significant increases in search activity, indicating heightened investor interest potentially linked to clinical developments and FDA approvals.

Recent Clinical Updates: Companies like Tectonic Therapeutics and SAB BIO have reported positive interim data from clinical trials, while others like CARGO Therapeutics are restructuring their operations following safety concerns in their studies.

Telomir Pharmaceuticals' Breakthrough: Telomir Pharmaceuticals announced promising preclinical findings for its lead compound, Telomir-1, which shows strong copper-binding potential as a treatment for Wilson's disease and related disorders, offering a safer alternative to current therapies.

Future Development Plans: The company is preparing for IND-enabling studies in 2025, with plans for first-in-human clinical trials by mid-2026, while also exploring applications of Telomir-1 in veterinary medicine and other diseases like Type 2 diabetes.

Telomir Pharmaceuticals' Breakthrough: Telomir Pharmaceuticals announced promising preclinical results for its molecule Telomir-1, showing significant improvements in Type 2 diabetes parameters, including reduced fasting plasma glucose and improved insulin sensitivity, along with increased survival rates in treated subjects.

Future Research Directions: The company is expanding research on Telomir-1's effects on various conditions such as progeria, Alzheimer's disease, osteoarthritis, and cancer, while also reporting a notable increase in their stock price following these findings.

Nikola Corporation Stock Decline: Nikola Corporation's shares fell 10.4% to $7.28 after announcing a securities purchase agreement and filing for a mixed shelf offering.

Significant Stock Gainers and Losers: Alzamend Neuro saw a 262% increase following a partnership announcement, while Liquidia Corporation experienced a 39% drop despite FDA approval for its inhalation powder.

Q2 2024 Earnings Report: Telomir Pharmaceuticals reported a second quarter earnings per share of -5 cents, with no revenue generated during the period.

Automated Earnings Coverage: InvestorPlace Earnings utilizes TradeSmith data to provide automated summaries of quarterly earnings reports, ensuring timely updates on key financial figures without human intervention.

Leadership Changes at Telomir: Erez Aminov has been appointed as the new CEO and Chairman of Telomir Pharmaceuticals following the passing of former Chairman Christopher Chapman, Jr. Three directors have resigned from the board, while three new members have been appointed to support the transition.

Company Focus: Telomir Pharmaceuticals is a pre-clinical-stage company dedicated to developing Telomir-1, a drug aimed at promoting longevity by addressing age-related conditions in humans and dogs through the protection of telomeres.

Leadership Changes at Telomir Pharmaceuticals: Telomir Pharmaceuticals announced the passing of CEO Christopher Chapman, Jr., and appointed Erez Aminov as the new Chairman and CEO.

Board Restructuring: Three directors from Telomir's Board have resigned, with Matthew Del Giudice, Ned MacPherson, and Matthew Pratt Whalen appointed as their replacements.

• FMW Media's "New to The Street" national business show will air on Bloomberg TV featuring corporate interviews with Telomir Pharmaceuticals, La Rosa Holdings Corp, Performance Golf, and Gondola.

• Telomir is a pharmaceutical company focused on developing a drug, TELOMIR-1, to increase telomere lengths and combat aging-related diseases.

• LRHC is revolutionizing the real estate market with an agent-centric model, innovative technology, and AI platform for better service.

• Performance Golf is an online platform offering golf instruction from top coaches, specialized clubs, and AI technology for personalized coaching.

• Gondola offers a financial product, MySafeTank™, providing low-risk investment options with built-in guarantees for retail investors.